Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
CD40 Ligand/TNFSF5 Antibody (MR-1), mFluor Violet 610 SE, Novus Biologicals™

Armenian Hamster Monoclonal Antibody
Supplier: Novus Biologicals NBP147234MFV610
Description
CD40 Ligand/TNFSF5 Monoclonal antibody specifically detects CD40 Ligand/TNFSF5 in Mouse samples. It is validated for Flow Cytometry, Immunohistochemistry, Immunocytochemistry/ Immunofluorescence, Immunoprecipitation, Immunohistochemistry (Paraffin), CyTOFSpecifications
CD40 Ligand/TNFSF5 | |
Monoclonal | |
mFluor Violet 610 SE | |
50mM Sodium Borate | |
Armenian Hamster | |
Protein A purified | |
RUO | |
Primary | |
Mouse | |
Purified |
Flow Cytometry, Immunohistochemistry, Immunocytochemistry, Immunoprecipitation, Immunohistochemistry (Paraffin), CyTOF | |
MR-1 | |
Flow Cytometry, Immunohistochemistry, Immunocytochemistry/ Immunofluorescence, Immunoprecipitation, Immunohistochemistry-Paraffin, CyTOF-ready | |
CD154, CD154 antigen, CD40 antigen ligand, CD40 ligand, CD40-L, CD40LIGM, gp39, hCD40L, HIGM1, T-B cell-activating molecule, T-BAM, T-cell antigen Gp39, TNF-related activation protein, TNFSF5IMD3, TRAPtumor necrosis factor (ligand) superfamily, member 5 (hyper-IgM syndrome), tumor necrosis factor (ligand) superfamily member 5, Tumor necrosis factor ligand superfamily member 5 | |
Activated mouse Th1 clone D1.6 | |
0.1 mL | |
Adaptive Immunity, Apoptosis, Asthma, Biologically Active Proteins, Breast Cancer, Cancer, Cell Biology, Cellular Markers, Endothelial Cell Markers, Hematopoietic Stem Cell Markers, Hypoxia, Immunology, Innate Immunity, Mast Cell Markers, Mesenchymal Stem Cell Markers, Myeloid Cell Markers, Neuronal Cell Markers, Neuroscience, Stem Cell Markers, Tumor Suppressors | |
959 | |
Store at 4C in the dark. | |
IgG1 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction